Psychopharmacology

Journal Title：Psychopharmacology

Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.

欧洲行为药理学会 (EBPS) 官方期刊

Psychopharmacology 是一本国际期刊，涵盖阐明药物影响行为的机制的广泛主题。期刊范围包括以下领域：

人类精神药理学：实验性

本部分包括描述药物对人类情绪、行为、认知和生理学影响的手稿。该杂志鼓励提交涉及脑成像、遗传学、神经内分泌学和发育主题的论文。本节中的手稿通常描述在受控条件下进行的研究，但偶尔也会考虑描述性或观察性研究。

人类精神药理学：临床和转化

本节包含针对药物与精神疾病广泛交叉领域的研究。这不仅包括药物使用和代谢、药物监测和药物流行病学的临床试验和研究，还包括利用整个临床相关方法学的工作，包括神经影像学、药物遗传学、认知科学、生物标志物等。特别鼓励将临床前知识转化为临床知识的工作。提交给本节的主要特点是它们涉及对临床方面的关注。

临床前精神药理学：行为和神经

本部分考虑了有关具有明确化学结构的化合物对人类以外的物种行为的任何方面的影响的报告，特别是与神经化学影响相关时。欢迎包含神经科学技术和行为的手稿。我们鼓励在行为和分子水平上提供深入了解药物作用机制的研究报告。

临床前精神药理学：转化

本部分考虑使用与疾病相关的临床前模型和测试来增强对可能对精神病或神经病患者具有治疗价值的中心机制的信心的手稿，或者报告可能成为临床前操作和挑战的手稿翻译到诊所。还将考虑旨在基于临床发现（反向翻译）改进临床前模型的研究。该杂志特别鼓励提交整合靶组织暴露、分子靶点活性和/或靶向生化途径调节的措施。

临床前精神药理学：分子、遗传和表观遗传

本节重点介绍神经药物/药物的分子和细胞作用，以及在健康和疾病中影响 CNS 的药物靶点的识别/验证。我们特别鼓励在分子水平上深入了解药物作用机制的研究。欢迎提供包含遗传或表观遗传对神经化学或行为影响证据的手稿。

Psychopharmacology创刊于1959年，由SPRINGER出版商出版，收稿方向涵盖医学 - 精神病学全领域，此刊是中等级别的SCI期刊，所以过审相对来讲不是特别难，但是该刊专业认可度不错，仍然是一本值得选择的SCI期刊 。平均审稿速度较快,2-4周，影响因子指数3.13，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。